Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of P28GST Treatment in Crohn's Disease Patients
NCT02281916Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Mar 2014
- Primary completion
- Feb 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rSh28GST in Crohn's disease, sponsored by CHU de Lille. Primary endpoint: Number of participants with adverse events at 1 year. Started Mar 2014; status: completed.
02
Drugs
rSh28GST
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02281916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281916.